Barchart.com
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Blackrock Technology and Private Equity Term Tru (BTX)

Blackrock Technology and Private Equity Term Tru (BTX)
5.50 x 1 6.79 x 1
Post-market by (Cboe BZX)
5.50 -0.10 (-1.79%) 04/07/25 [NYSE]
5.50 x 1 6.79 x 1
Post-market 5.50 unch (unch) 19:00 ET
News & Headlines for Mon, Apr 7th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer Globe Newswire - Tue Jul 26, 2022

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Globe Newswire - Fri Jun 17, 2022

SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Announces Board Changes Globe Newswire - Tue Jun 7, 2022

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting Globe Newswire - Tue May 31, 2022

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q Globe Newswire - Fri May 27, 2022

SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines Globe Newswire - Thu Apr 21, 2022

Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunology...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results Globe Newswire - Fri Apr 15, 2022

SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement Globe Newswire - Wed Mar 9, 2022

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors Globe Newswire - Thu Jan 20, 2022

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 5.50 (-1.79%)
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio Globe Newswire - Thu Jan 13, 2022

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...

BTX : 5.50 (-1.79%)

Barchart Exclusives

Bank of America Says This 1 Dividend Stock Is a Top Buy for Q2 Barchart - Mon Apr 7, 6:30PM CDT
Bank of America has named Energy Transfer as a top dividend stock for Q2 2025, citing its strong financials, strategic growth initiatives, and attractive 8% forward dividend yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades
Wed, Apr 09, 2025 5:00 PM UTC
Reserve Your Spot